Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,521.44
(
0.33%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
91.36
(
-0.89%
)
Bitcoin
73,359.77
(
-0.24%
)
News Focus
News Focus
Post# of 257659
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123038
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: shareholder_boar post# 185612

Wednesday, 01/07/2015 2:00:43 PM

Wednesday, January 07, 2015 2:00:43 PM

Post# of 257659
Yes, ABBV has the legal right to add another drug to the ABT-493/ABT-530 next-generation regimen; however, from a practical standpoint, it wouldn’t be good for ABBV’s (very productive) partnership with ENTA if ABBV were to make such a decision unilaterally—unless ABBV were intending to drop ABT-493 altogether. Regards, Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today